An innovative haircare active ingredient based on stem cell science and technology developed by Medipost and commercialized by Celino in Korea and worldwide
2. 01
Stem cell conditioned media
• Stem cell conditioned media is a collection of signal transduction molecules (i.e. growth factors,
cytokines and chemokines) secreted by stem cell during proliferation or differentiation, having a
proven potency to activate aging indigenous cells including hair follicular cells
• Stem cell conditioned media thus is able to reverse or at least delay skin aging process if used as
an active ingredient for desired purposes
Activation of indigenous cells
3. 01
NGF-574H: primed stem cell conditioned media for hair growth
• Human stem cell conditioned media is allowed to be used in cosmetic products in advanced
countries like US, Japan and Korea by regulatory authorities;
• The composition of the conditioned media can be controlled by appropriate pretreatment of the
stem cells prior to secretion of trophic factors (process called “priming”);
• NGF-574H is a human cord blood derived stem cell (hUCB-MSC) conditioned media optimized to
facilitate hair growth by Medipost’s proprietary priming technology.
4. 01
• The primed conditioned media candidates were tested for hair growth potency;
• NGF-574H (CM-3) resulted in 51% increase compared with control in hair length in ex vivo
experiment with human hair follicles.
POC: ex vivo experiment with human hair follicles
5. 01
POC (2): clinical studies
Phototrichogram for hair density
hair density hair diameter hair growth rate
• A toxicity study was completed based on the MFDS (KFDA) guideline;
• A POC clinical trial was designed in total 16 weeks use once daily by topical administration;
• Total 30 subjects were tested in a placebo controlled double blind trial;
• Subject groups using a formulation containing 5% NGF-574H showed superiority in total hair
count (hair density), hair diameter and hair growth rate compared with placebo control group
(treated with vehicle formulation only).
6. • Despite shorter length of treatment period (16w vs.48 w), the efficacy of NGF-574H seems
comparable or even superior to medications available in the market for alopecia.
*
Subject #
tested
Dosing period Protocol
Hair density
improvement
(in cm^2)
Hair density
improvement
(%)
Manufacturer
NGF-574H 30 16w
NGF-574H 5% solution,
1x/day, topical
13.4 13.8% MEDIPOST
Minoxidil
(Rogain)
393 48w
Minoxidil 2% solution,
2X/day , topical
12.7 8.8% Roche
Minoxidil
(Rogain)
393 48w
Minoxidil 5% solution,
2X/day , topical
18.6 12.3% Roche
Finasteride
(Prosca)
693 36w
Finasteride 5mg tab,
1X/day, oral
12.9 7.7% MSD
Dutasteride
(Avodart)
416 36w
Dutasteride 0.1mg tab,
1X/day, oral
15.4 8.7% GSK
POC (3): Efficacy comparison (literature survey)
7. Current Status
• Awarded New Excellent Health Technology by Ministry of Health and Welfare Korea;
• Bigger scale 24 week POC clinical trial (total 84 male and female subjects) for 24 weeks will be
completed in Aug 2019;
• Patent pending in major countries including US and Japan
• Market launch is due in 3Q 2019 exclusive for clinics and hospitals.
